Pfizer, BioNTech start trial for third booster dose against new Covid-19 variants
The Phase 1/2/3 trial evaluates the safety and tolerability of a third dose of BNT162b2 and its effectiveness…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Feb 21
The Phase 1/2/3 trial evaluates the safety and tolerability of a third dose of BNT162b2 and its effectiveness…
25 Feb 21
AbbVie claims that HUMIRA is the first and only subcutaneous biologic treatment for active ulcerative colitis in paediatric…
25 Feb 21
PRA shareholders will own around 34% of the shares of the combined company and ICON shareholders will own…
23 Feb 21
The Phase 2 trial is designed to determine the appropriate antigen dosage for Phase 3 evaluation of their…
19 Feb 21
The Phase 2/3 study will enrol healthy pregnant women, aged 18 years and older, and vaccinate them during…
18 Feb 21
The companies initially signed an agreement in April 2020 to discover and develop new therapies for coronaviruses
17 Feb 21
Entresto benefits patients with both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection…
16 Feb 21
Plavix is an antiplatelet medication or blood thinner, intended to reduce the risk of heart disease and stroke…
15 Feb 21
Panzyga was previously approved in the US to treat primary humoral immunodeficiency in people aged two years and…
15 Feb 21
The EC approval allows the sale of Ogluo in all 27 European Union (EU) member countries, along with…